

International Law Talk Podcast: EU Competition Law Developments in the Pharmaceutical Sector with Michael Clancy and David Hull

Kluwer Competition Law Blog
June 3, 2021

Lena Hornkohl (Deputy Editor) (Max Planck Institute Luxembourg for Procedural Law)

Please refer to this post as: Lena Hornkohl (Deputy Editor), 'International Law Talk Podcast: EU Competition Law Developments in the Pharmaceutical Sector with Michael Clancy and David Hull', Kluwer Competition Law Blog, June 3, 2021, <http://competitionlawblog.kluwercompetitionlaw.com/2021/06/03/international-law-talk-podcast-eu-competition-law-developments-in-the-pharmaceutical-sector-with-michael-clancy-and-david-hull/>

We are happy to announce the new International Law Talk Podcast episode on EU competition law developments in the pharmaceutical sector. And this one is twice as good! Not only are we discussing both competition and IP issues, but I also interviewed two leading experts in the field: Michael Clancy and David Hull from Van Bael & Bellis.

In the podcast, we touch upon new pharma developments regarding the Covid IP waivers, patent settlements, patent late life cycle strategies, biosimilars, excessive pricing, merger control and much more. [Listen to the podcast!](#)

In case you want to learn more on competition law and pharma, the new edition of the book by Van Bael & Bellis on [Competition Law of the European Union](#) has a great new section on the topic.